Analysts’ Recent Ratings Changes for Sight Sciences (SGHT)

Sight Sciences (NASDAQ: SGHT) has recently received a number of price target changes and ratings updates:

• 8/13/2026 – Sight Sciences had its “neutral” rating reaffirmed by Citigroup Inc..
• 8/8/2026 – Sight Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Sight Sciences had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/6/2026 – Sight Sciences had its price target raised by UBS Group AG from $7.00 to $8.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Sight Sciences is now covered by UBS Group AG. They set a “buy” rating and a $7.00 price target on the stock.
• 7/8/2026 – Sight Sciences had its price target raised by Citigroup Inc. from $5.15 to $6.00. They now have a “neutral” rating on the stock.

Insiders Place Their Bets

In other Sight Sciences news, CFO James Rodberg sold 6,902 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $5.36, for a total value of $36,994.72. Following the completion of the sale, the chief financial officer directly owned 224,037 shares in the company, valued at $1,200,838.32. This trade represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jeremy B. Hayden sold 12,733 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.51, for a total value of $70,158.83. Following the completion of the transaction, the insider owned 357,037 shares of the company’s stock, valued at approximately $1,967,273.87. The trade was a 3.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 58,566 shares of company stock worth $318,827. Insiders own 30.40% of the company’s stock.

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.